SABCS 2018

Area: Oncology

Location: San Antonio, United States

Date: December 4 to December 8

Description:

41st Annual San Antonio Breast Cancer Symposium.


Search in Scientific Content:
Date
Filters:
Effects of
11:15

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Presenter: Richard Gray
Oncology : Breast Cancer
Alpelisib
14:48

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Presenter: Dejan Juric
Oncology : Breast Cancer
Lifestyle
8:40

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Presenter: Wolfgang Janni
Oncology : Breast Cancer
Choice of
8:39

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Presenter: Laura Dominici
Oncology : Breast Cancer
Circulatin
10:32

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Presenter: Francois-Clement Bidard
Oncology : Breast Cancer
Axillary R
9:45

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Presenter: Emiel J. T. Rutgers
Oncology : Breast Cancer
Accelerate
6:19

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Presenter: Fank Vicini
Oncology : Breast Cancer
A randomiz
10:32

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

Presenter: Andrea De Censi
Oncology : Breast Cancer
PALLET: A
12:51

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Presenter: Mitchell Dowsett
Oncology : Breast Cancer
Phase III
9:33

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Presenter: Charles E. Geyer, Jr
Oncology : Breast Cancer
Adjuvant C
8:05

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Presenter: Miguel Martín
Oncology : Breast Cancer
Adjuvant C
7:33

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Presenter: Laura Spring
Oncology : Breast Cancer
Delaying A
5:48

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Presenter: Zaida Morante
Oncology : Breast Cancer
Low-Dose T
9:12

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Presenter: Andrea De Censi
Oncology : Breast Cancer
Beyond B c
4:12

Beyond B cells: Targeting BCL-2 pro-survival proteins in breast cancer

Presenter: Geoffrey Lindeman
Oncology : Breast Cancer
Results fr
2:39

Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

Presenter: Francisco J. Esteva
Oncology : Breast Cancer
Management
3:17

Management of the Axilla After Neoadjuvant Therapy: Beyond the Clinical Trials

Presenter: Monica Morrow
Oncology : Breast Cancer
Oxybutynin
6:17

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors

Presenter: Roberto A. Leon Ferre
Oncology : Breast Cancer
ALEXANDRA/
12:05

ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer

Presenter: Heather L. McArthur
Oncology : Breast Cancer
Incidence
4:08

Incidence of late relapse in HER2-positive (HER2+) breast cancer patients receiving adjuvant trastuzumab: Combined analysis of NCCTG (Alliance) N9831 and NSABP (NRG) B31

Presenter: Saranya Chumsri
Oncology : Breast Cancer
The curren
15:18

The current trends in the treatment of breast cancer

Presenter: Gabriel N. Hortobagyi
Oncology : Breast Cancer
Phase 2 sa
2:33

Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus

Presenter: Jennifer R. Diamond
Oncology : Breast Cancer
ALEXANDRA/
6:23

ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer

Presenter: Michail Ignatiadis
Oncology : Breast Cancer
Use of 64C
2:25

Use of 64Cu-DOTA-trastuzumab positron emission tomography (PET) to predict response to ado-trastuzumab emtansine (TDM1)

Presenter: Joanne Mortimer
Oncology : Breast Cancer
Prognostic
2:24

Prognostic value of residual cancer burden (RCB), neo-bioscore and neoadjuvant response index (NRI) to evaluate response to neoadjuvant trastuzumab-based therapy in HER2-positive breast cancer (BC)

Presenter: Tessa Gerjanne Steenbruggen
Oncology : Breast Cancer
Dissecting
4:43

Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial

Presenter: Matteo Lambertini
Oncology : Breast Cancer
Analysis o
4:00

Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease with initially diagnosed HER2+ breast cancer: NSABP FB-10

Presenter: Shannon L. Puhalla
Oncology : Breast Cancer
Lifestyle
3:42

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Presenter: Wolfgang Janni
Oncology : Breast Cancer
Low-Dose T
3:35

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Presenter: Andrea De Censi
Oncology : Breast Cancer
Revolution
5:28

Revolution of Cancer Immunotherapy

Presenter: Leisha A. Emens
Oncology : Breast Cancer

ASCO 2021

2021-06-04 - 2021-06-08
Online, Virtual

St. Gallen BCC 2021

2021-03-17 - 2021-03-21
Online, Virtual

SABCS 2020

2020-12-08 - 2020-12-11
Online, Virtual

ESMO 2020

2020-09-19 - 2020-09-21
Online, Virtual

ASCO 2020

2020-05-29 - 2020-05-31
Online, Virtual

ESMO 2019

2019-09-27 - 2019-10-01
Barcelona, Spain

ASCO 2019

2019-05-31 - 2019-06-04
Chicago, United States

EADO 2019

2019-04-24 - 2019-04-27
Paris, France

BCC 2019

2019-03-20 - 2018-03-23
Vienna, Austria